2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 63.347 | 125.542 | 145.630 | 76.085 | 84.016 | 93.108 | 137.104 | 116.326 | 110.252 | 128.656 |
Total Income - EUR | 63.348 | 126.175 | 145.634 | 76.981 | 84.022 | 93.304 | 142.667 | 116.329 | 113.323 | 136.852 |
Total Expenses - EUR | 51.246 | 100.253 | 106.073 | 49.412 | 38.210 | 36.059 | 64.005 | 36.917 | 39.493 | 49.448 |
Gross Profit/Loss - EUR | 12.103 | 25.922 | 39.561 | 27.568 | 45.812 | 57.245 | 78.662 | 79.412 | 73.829 | 87.404 |
Net Profit/Loss - EUR | 10.203 | 22.290 | 33.796 | 26.727 | 44.972 | 56.438 | 77.585 | 78.470 | 72.894 | 86.442 |
Employees | 8 | 15 | 16 | 7 | 5 | 5 | 5 | 5 | 5 | 4 |
Check the financial reports for the company - Curaxim Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 33.214 | 29.827 | 22.950 | 16.361 | 11.982 | 4.410 | 0 | 0 | 0 | 1.805 |
Current Assets | 17.957 | 48.324 | 25.799 | 30.564 | 45.881 | 70.002 | 87.063 | 81.283 | 77.058 | 86.668 |
Inventories | 691 | 830 | 175 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Receivables | 15.776 | 17.715 | 21.668 | 26.246 | 29.672 | 61.493 | 60.752 | 73.186 | 62.074 | 70.390 |
Cash | 1.489 | 29.779 | 3.955 | 4.318 | 16.209 | 8.509 | 26.312 | 8.098 | 14.985 | 16.278 |
Shareholders Funds | 40.820 | 63.450 | 41.683 | 44.390 | 52.583 | 56.489 | 77.635 | 78.518 | 72.942 | 86.490 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 12.049 | 15.766 | 8.074 | 3.462 | 6.092 | 18.704 | 10.159 | 3.608 | 4.951 | 2.372 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "8129 - 8129" | |||||||||
CAEN Financial Year |
8129
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Curaxim Srl